Characteristics of Candida albicans biofilms grown in a synthetic urine medium

Journal of Clinical Microbiology

Volumn 47, Issue 12, 2009, Pages 4078-4083

  Uppuluri, Priya ^a   Dinakaran, Hemamalini ^a   Thomas, Derek P ^a   Chaturvedi, Ashok K ^a   Lopez Ribot, Jose L ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 BIS(2 METHOXY 4 NITRO 5 SULFOPHENYL) 2H TETRAZOLIUM 5 CARBOXANILIDE; AMPHOTERICIN B; CASPOFUNGIN; ELASTOMER; FLUCONAZOLE; SILICON; TETRAZOLIUM; UNCLASSIFIED DRUG;

ANTIFUNGAL RESISTANCE; ARTICLE; BIOFILM; CANDIDA ALBICANS; CELL ADHESION; CELL GROWTH; CELL MATURATION; CULTURE MEDIUM; FUNGUS GROWTH; GENE EXPRESSION PROFILING; HOSPITAL INFECTION; IN VITRO STUDY; INDWELLING CATHETER; INFECTION RISK; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; URINARY CATHETER; URINARY TRACT INFECTION;

ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; CULTURE MEDIA; ECHINOCANDINS; FUNGAL PROTEINS; GENE EXPRESSION PROFILING; HUMANS; MICROBIAL SENSITIVITY TESTS; SILICONE ELASTOMERS; URINE;

CANDIDA ALBICANS;

EID: 71549141614     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.01377-09     Document Type: Article

References (32)

1. Bachmann, S. P., K. VandeWalle, G. Ramage, T. F. Patterson, B. L. Wickes, J. R. Graybill, and J. L. Lopez-Ribot. 2002. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob. Agents Chemother. 46:3591-3596.
2. Braun, B. R., and A. D. Johnson. 1997. Control of filament formation in Candida albicans by the transcriptional repressor TUP1. Science 277:105-109.
3. Braun, B. R., D. Kadosh, and A. D. Johnson. 2001. NRG1, a repressor of filamentous growth in C. albicans, is down-regulated during filament induction. EMBO J. 20:4753-4761.
4. Chandra, J., D. M. Kuhn, P. K. Mukherjee, L. L. Hoyer, T. McCormick, and M. A. Ghannoum. 2001. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J. Bacteriol. 183:5385-5394.
5. Cocuaud, C., M. H. Rodier, G. Daniault, and C. Imbert. 2005. Anti-metabolic activity of caspofungin against Candida albicans and Candida parapsilosis biofilms. J. Antimicrob. Chemother. 56:507-512.
6. Domergue, R., I. Castano, A. De Las Penas, M. Zupancic, V. Lockatell, J. R. Hebel, D. Johnson, and B. P. Cormack. 2005. Nicotinic acid limitation regulates silencing of Candida adhesins during UTI. Science 308:866-870.
7. Jain, N., R. Kohli, E. Cook, P. Gialanella, T. Chang, and B. C. Fries. 2007. Biofilm formation by and antifungal susceptibility of Candida isolates from urine. Appl. Environ. Microbiol. 73:1697-1703.
8. Kojic, E. M., and R. O. Darouiche. 2004. Candida infections of medical devices. Clin. Microbiol. Rev. 17:255-267.
9. Kuhn, D. M., and M. A. Ghannoum. 2004. Candida biofilms: antifungal resistance and emerging therapeutic options. Curr. Opin. Investig. Drugs 5:186-197.
10. LaFleur, M. D., C. A. Kumamoto, and K. Lewis. 2006. Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob. Agents Chemother. 50:3839-3846.
11. Maki, D. G., and P. A. Tambyah. 2001. Engineering out the risk for infection with urinary catheters. Emerg. Infect. Dis. 7:342-347.
12. Michea, L., D. R. Ferguson, E. M. Peters, P. M. Andrews, M. R. Kirby, and M. B. Burg. 2000. Cell cycle delay and apoptosis are induced by high salt and urea in renal medullary cells. Am. J. Physiol. Renal Physiol. 278:F209-F218.
13. Nailis, H., T. Coenye, F. Van Nieuwerburgh, D. Deforce, and H. J. Nelis. 2006. Development and evaluation of different normalization strategies for gene expression studies in Candida albicans biofilms by real-time PCR. BMC Mol. Biol. 7:25.
14. Nett, J., and D. Andes. 2006. Candida albicans biofilm development, modeling a host-pathogen interaction. Curr. Opin. Microbiol. 9:340-345.
15. Nobile, C. J., H. A. Schneider, J. E. Nett, D. C. Sheppard, S. G. Filler, D. R. Andes, and A. P. Mitchell. 2008. Complementary adhesin function in C. albicans biofilm formation. Curr. Biol. 18:1017-1024.
16. Park, C., K. Kim, J. Choi, and K. Park. 2007. Classification of glucose concentration in diluted urine using the low-resolution Raman spectroscopy and kernel optimization methods. Physiol. Meas. 28:583-593.
17. Perumal, P., S. Mekala, and W. L. Chaffin. 2007. Role for cell density in antifungal drug resistance in Candida albicans biofilms. Antimicrob. Agents Chemother. 51:2454-2463.
18. Pierce, C. G., P. Uppuluri, A. R. Tristan, F. L. Wormley, Jr., E. Mowat, G. Ramage, and J. L. Lopez-Ribot. 2008. A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat. Protoc. 3:1494-1500.
19. Ramage, G., J. P. Martinez, and J. L. Lopez-Ribot. 2006. Candida biofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Res. 6:979-986.
20. Ramage, G., S. P. Saville, D. P. Thomas, and J. L. Lopez-Ribot. 2005. Candida biofilms: an update. Eukaryot. Cell 4:633-638.
21. Ramage, G., K. VandeWalle, S. P. Bachmann, B. L. Wickes, and J. L. Lopez-Ribot. 2002. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob. Agents Chemother. 46:3634-3636.
22. Ramage, G., K. VandeWalle, J. L. Lopez-Ribot, and B. L. Wickes. 2002. The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol. Lett. 214:95-100. (Pubitemid 35245528)
23. Ramage, G., K. Vandewalle, B. L. Wickes, and J. L. Lopez-Ribot. 2001. Characteristics of biofilm formation by Candida albicans. Rev. Iberoam Micol. 18:163-170.
24. Ramage, G., B. L. Wickes, and J. L. Lopez-Ribot. 2008. A seed and feed model for the formation of Candida albicans biofilms under flow conditions using an improved modified Robbins device. Rev. Iberoam. Micol. 25:37-40.
25. Richard, M. L., C. J. Nobile, V. M. Bruno, and A. P. Mitchell. 2005. Candida albicans biofilm-defective mutants. Eukaryot. Cell 4:1493-1502.
26. Richards, M. J., J. R. Edwards, D. H. Culver, R. P. Gaynes, et al. 1999. Nosocomial infections in medical intensive care units in the United States. Crit. Care Med. 27:887-892.
27. Sobel, J. D., S. K. Bradshaw, C. J. Lipka, and N. A. Kartsonis. 2007. Caspofungin in the treatment of symptomatic candiduria. Clin. Infect. Dis. 44:e46-e49.
28. Stoldt, V. R., A. Sonneborn, C. E. Leuker, and J. F. Ernst. 1997. Efg1p, an essential regulator of morphogenesis of the human pathogen Candida albicans, is a member of a conserved class of bHLH proteins regulating morphogenetic processes in fungi. EMBO J. 16:1982-1991.
29. Toyoda, M., T. Cho, H. Kaminishi, M. Sudoh, and H. Chibana. 2004. Transcriptional profiling of the early stages of germination in Candida albicans by real-time RT-PCR. FEMS Yeast Res. 5:287-296.
30. Uppuluri, P., A. K. Chaturvedi, and J. L. Lopez-Ribot. 2009. Design of a simple model of Candida albicans biofilms formed under conditions of flow: development, architecture, and drug Resistance. Mycopathologia 168:101-109.
31. Uppuluri, P., J. Nett, J. Heitman, and D. Andes. 2008. Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob. Agents Chemother. 52:1127-1132.
32. Zhao, R., K. J. Daniels, S. R. Lockhart, K. M. Yeater, L. L. Hoyer, and D. R. Soll. 2005. Unique aspects of gene expression during Candida albicans mating and possible G1 dependency. Eukaryot. Cell 4:1175-1190.